These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15982873)

  • 1. A preliminary study of the metabolic stability of a series of benzoxazinone derivatives as potent neuropeptide Y5 antagonists.
    Dordal A; Lipkin M; Macritchie J; Mas J; Port A; Rose S; Salgado L; Savic V; Schmidt W; Serafini MT; Spearing W; Torrens A; Yeste S
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3679-84. PubMed ID: 15982873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity.
    Torrens A; Mas J; Port A; Castrillo JA; Sanfeliu O; Guitart X; Dordal A; Romero G; Fisas MA; Sánchez E; Hernández E; Pérez P; Pérez R; Buschmann H
    J Med Chem; 2005 Mar; 48(6):2080-92. PubMed ID: 15771450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel potent neuropeptide Y Y5 receptor antagonists: synthesis and structure-activity relationships of phenylpiperazine derivatives.
    Takahashi T; Sakuraba A; Hirohashi T; Shibata T; Hirose M; Haga Y; Nonoshita K; Kanno T; Ito J; Iwaasa H; Kanatani A; Fukami T; Sato N
    Bioorg Med Chem; 2006 Nov; 14(22):7501-11. PubMed ID: 16919461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative structure activity relationship of benzoxazinone derivatives as neuropeptide Y Y5 receptor antagonists.
    Deswal S; Roy N
    Eur J Med Chem; 2006 Apr; 41(4):552-7. PubMed ID: 16545499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of new arylsulfonamidomethylcyclohexyl derivatives as human neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
    Moreno A; Pérez S; Galiano S; Juanenea L; Erviti O; Frígola C; Aldana I; Monge A
    Eur J Med Chem; 2004 Jan; 39(1):49-58. PubMed ID: 14987833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure activity relationship of guanidines as NPY Y5 antagonists.
    Aquino CJ; Ramanjulu JM; Heyer D; Daniels AJ; Palazzo F; Dezube M
    Bioorg Med Chem; 2004 May; 12(10):2691-708. PubMed ID: 15110851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and structure-activity relationship of a novel spirocarbamate series of NPY Y5 antagonists.
    Leslie CP; Bentley J; Biagetti M; Contini S; Di Fabio R; Donati D; Genski T; Guery S; Mazzali A; Merlo G; Pizzi DA; Sacco F; Seri C; Tessari M; Zonzini L; Caberlotto L
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6103-7. PubMed ID: 20813523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and SAR of substituted tetrahydrocarbazole derivatives as new NPY-1 antagonists.
    Di Fabio R; Giovannini R; Bertani B; Borriello M; Bozzoli A; Donati D; Falchi A; Ghirlanda D; Leslie CP; Pecunioso A; Rumboldt G; Spada S
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1749-52. PubMed ID: 16364642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.
    Ogino Y; Ohtake N; Nagae Y; Matsuda K; Moriya M; Suga T; Ishikawa M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5010-4. PubMed ID: 18723347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles: potent and selective neuropeptide Y Y5-receptor antagonists.
    Blum CA; Zheng X; De Lombaert S
    J Med Chem; 2004 Apr; 47(9):2318-25. PubMed ID: 15084130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of new hydrazide derivatives as neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
    Juanenea L; Galiano S; Erviti O; Moreno A; Pérez S; Aldana I; Monge A
    Bioorg Med Chem; 2004 Sep; 12(17):4717-23. PubMed ID: 15358298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.
    Ogino Y; Ohtake N; Nagae Y; Matsuda K; Ishikawa M; Moriya M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4997-5001. PubMed ID: 18752943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and SAR of a novel series of benzimidazoles as potent NPY Y5 antagonists.
    Pizzi DA; Leslie CP; Mazzali A; Seri C; Biagetti M; Bentley J; Genski T; Di Fabio R; Contini S; Sabbatini FM; Zonzini L; Caberlotto L
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7120-3. PubMed ID: 20951033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists.
    Biagetti M; Leslie CP; Mazzali A; Seri C; Pizzi DA; Bentley J; Genski T; Di Fabio R; Zonzini L; Caberlotto L
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4741-4. PubMed ID: 20630754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists.
    Sato N; Jitsuoka M; Ishikawa S; Nagai K; Tsuge H; Ando M; Okamoto O; Iwaasa H; Gomori A; Ishihara A; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1670-4. PubMed ID: 19233647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and evaluation of a novel cyclohexanamine class of neuropeptide Y Y1 receptor antagonists.
    Cho K; Ando M; Kobayashi K; Miyazoe H; Tsujino T; Ito S; Suzuki T; Tanaka T; Tokita S; Sato N
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4781-5. PubMed ID: 19596193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand.
    Mullins D; Adham N; Hesk D; Wu Y; Kelly J; Huang Y; Guzzi M; Zhang X; McCombie S; Stamford A; Parker E
    Eur J Pharmacol; 2008 Dec; 601(1-3):1-7. PubMed ID: 18976648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel orally active ureido NPY Y5 receptor antagonists.
    Li G; Stamford AW; Huang Y; Cheng KC; Cook J; Farley C; Gao J; Ghibaudi L; Greenlee WJ; Guzzi M; van Heek M; Hwa JJ; Kelly J; Mullins D; Parker EM; Wainhaus S; Zhang X
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1146-50. PubMed ID: 18160282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists.
    Norman MH; Chen N; Chen Z; Fotsch C; Hale C; Han N; Hurt R; Jenkins T; Kincaid J; Liu L; Lu Y; Moreno O; Santora VJ; Sonnenberg JD; Karbon W
    J Med Chem; 2000 Nov; 43(22):4288-312. PubMed ID: 11063624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of substituted 4-alkoxy-2-aminopyridines as novel neuropeptide Y1 receptor antagonists.
    Sato N; Shibata T; Jitsuoka M; Ohno T; Takahashi T; Hirohashi T; Kanno T; Iwaasa H; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2004 Apr; 14(7):1761-4. PubMed ID: 15026066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.